World journal of obstetrics and gynecology最新文献_第2页

Association of endometrioma with ovarian teratoma and mucinous cystadenoma in a patient diagnosed with endometriosis: A case report 子宫内膜异位症患者子宫内膜异位症与卵巢畸胎瘤和粘液囊腺瘤的关系:1例报告

World journal of obstetrics and gynecology Pub Date : 2019-12-27 DOI: 10.5317/wjog.v8.i2.8

Samaneh Rokhgireh, Abolfazl Mehdizadehkashi, K. Tahermanesh, Mansoureh Gorginzadeh

引用次数: 1

Endorphins, oxytocin, sexuality and romantic relationships: An understudied area 内啡肽，催产素，性和浪漫关系:一个研究不足的领域

World journal of obstetrics and gynecology Pub Date : 2018-10-22 DOI: 10.5317/WJOG.V7.I2.17

M. Khajehei, E. Behroozpour

引用次数: 10

Hypothyroidism during pregnancy: Controversy over screening and intervention 妊娠期甲状腺功能减退症：筛查和干预的争议

World journal of obstetrics and gynecology Pub Date : 2018-07-10 DOI: 10.5317/WJOG.V7.I1.1

A. Dirar, A. Kalhan

引用次数: 6

Cancer stem cells and early stage basal-like breast cancer. 癌症干细胞和早期基底样乳腺癌。

World journal of obstetrics and gynecology Pub Date : 2016-05-10 DOI: 10.5317/WJOG.v5.i2.150

Pang-Kuo Lo, Benjamin Wolfson, Qun Zhou

{"title":"Cancer stem cells and early stage basal-like breast cancer.","authors":"Pang-Kuo Lo, Benjamin Wolfson, Qun Zhou","doi":"10.5317/WJOG.v5.i2.150","DOIUrl":"https://doi.org/10.5317/WJOG.v5.i2.150","url":null,"abstract":"Ductal carcinoma in situ (DCIS) is a category of early stage, non-invasive breast tumor defined by the intraductal proliferation of malignant breast epithelial cells. DCIS is a heterogeneous disease composed of multiple molecular subtypes including luminal, HER2 and basal-like types, which are characterized by immunohistochemical analyses and gene expression profiling. Following surgical and radiation therapies, patients with luminal-type, estrogen receptor-positive DCIS breast tumors can benefit from adjuvant endocrine-based treatment. However, there are no available targeted therapies for patients with basal-like DCIS (BL-DCIS) tumors due to their frequent lack of endocrine receptors and HER2 amplification, rendering them potentially susceptible to recurrence. Moreover, multiple lines of evidence suggest that DCIS is a non-obligate precursor of invasive breast carcinoma. This raises the possibility that targeting precursor BL-DCIS is a promising strategy to prevent BL-DCIS patients from the development of invasive basal-like breast cancer. An accumulating body of evidence demonstrates the existence of cancer stem-like cells (CSCs) in BL-DCIS, which potentially determine the features of BL-DCIS and their ability to progress into invasive cancer. This review encompasses the current knowledge in regard to the characteristics of BL-DCIS, identification of CSCs, and their biological properties in BL-DCIS. We summarize recently discovered relevant molecular signaling alterations that promote the generation of CSCs in BL-DCIS and the progression of BL-DCIS to invasive breast cancer, as well as the influence of the tissue microenvironment on CSCs and the invasive transition. Finally, we discuss the translational implications of these findings for the prognosis and prevention of BL-DCIS relapse and progression.","PeriodicalId":91183,"journal":{"name":"World journal of obstetrics and gynecology","volume":"5 2","pages":"150-161"},"PeriodicalIF":0.0,"publicationDate":"2016-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/d2/nihms-799505.PMC5321620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34765964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival. 妇科肿瘤学家参与卵巢癌治疗标准的接受和生存。

World journal of obstetrics and gynecology Pub Date : 2016-01-01 Epub Date: 2016-05-10 DOI: 10.5317/wjog.v5.i2.187

Sun Hee Rim, Shawn Hirsch, Cheryll C Thomas, Wendy R Brewster, Darryl Cooney, Trevor D Thompson, Sherri L Stewart

{"title":"Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival.","authors":"Sun Hee Rim, Shawn Hirsch, Cheryll C Thomas, Wendy R Brewster, Darryl Cooney, Trevor D Thompson, Sherri L Stewart","doi":"10.5317/wjog.v5.i2.187","DOIUrl":"10.5317/wjog.v5.i2.187","url":null,"abstract":"Aim: To examine the influence of gynecologic oncologists (GO) in the United States on surgical/chemotherapeutic standard of care (SOC), and how this translates into improved survival among women with ovarian cancer (OC).Methods: Surveillance, Epidemiology, and End Result (SEER)-Medicare data were used to identify 11688 OC patients (1992-2006). Only Medicare recipients with an initial surgical procedure code (n = 6714) were included. Physician specialty was identified by linking SEER-Medicare to the American Medical Association Masterfile. SOC was defined by a panel of GOs. Multivariate logistic regression was used to determine predictors of receiving surgical/chemotherapeutic SOC and proportional hazards modeling to estimate the effect of SOC treatment and physician specialty on survival.Results: About 34% received surgery from a GO and 25% received the overall SOC. One-third of women had a GO involved sometime during their care. Women receiving surgery from a GO vs non-GO had 2.35 times the odds of receiving the surgical SOC and 1.25 times the odds of receiving chemotherapeutic SOC (P < 0.01). Risk of mortality was greater among women not receiving surgical SOC compared to those who did [hazard ratio = 1.22 (95%CI: 1.12-1.33), P < 0.01], and also was higher among women seen by non-GOs vs GOs (for surgical treatment) after adjusting for covariates. Median survival time was 14 mo longer for women receiving combined SOC.Conclusion: A survival advantage associated with receiving surgical SOC and overall treatment by a GO is supported. Persistent survival differences, particularly among those not receiving the SOC, require further investigation.","PeriodicalId":91183,"journal":{"name":"World journal of obstetrics and gynecology","volume":"5 2","pages":"187-196"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/56/nihms825502.PMC5839163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35897424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality. 妇科肿瘤学家的可用性对卵巢癌死亡率的影响。

World journal of obstetrics and gynecology Pub Date : 2014-05-01 Epub Date: 2014-05-10 DOI: 10.5317/wjog.v3.i2.71

Sherri L Stewart, Darryl Cooney, Shawn Hirsch, Lauren Westervelt, Thomas B Richards, Sun Hee Rim, Cheryll C Thomas

{"title":"The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality.","authors":"Sherri L Stewart, Darryl Cooney, Shawn Hirsch, Lauren Westervelt, Thomas B Richards, Sun Hee Rim, Cheryll C Thomas","doi":"10.5317/wjog.v3.i2.71","DOIUrl":"10.5317/wjog.v3.i2.71","url":null,"abstract":"Aim: To determine the association between the distribution of gynecologic oncologist (GO) and population-based ovarian cancer death rates.Materials and methods: Data on ovarian cancer incidence and mortality in the United States (U.S.) was supplemented with U.S. census data, and analyzed in relation to practicing GOs. GO locations were geocoded to link association between county variables and GO availability. Logistic regression was used to measure areas of high and low ovarian cancer mortality, adjusting for contextual variables.Results: Practicing GOs were unevenly distributed in the United States, with the greatest numbers in metropolitan areas. Ovarian cancer incidence and death rates increased as distance to a practicing GO increased. A relatively small number (153) of counties within 24 miles of a GO had high ovarian cancer death rates compared to 577 counties located 50 or more miles away with high ovarian cancer death rates. Counties located 50 or more miles away from a GO practice had an almost 60% greater odds of high ovarian cancer mortality compared to those with closer practicing GOs (OR 1.59, 95% CI 1.18-2.15).Conclusion: The distribution of GOs across the United States appears to be significantly associated with ovarian cancer mortality. Efforts that facilitate outreach of GOs to certain populations may increase geographic access. Future studies examining other factors associated with lack of GO access (e.g. insurance and other socioeconomic factors) at the individual level will assist with further defining barriers to quality ovarian cancer care in the United States.","PeriodicalId":91183,"journal":{"name":"World journal of obstetrics and gynecology","volume":"3 2","pages":"71-77"},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605894/pdf/nihms725368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34096279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0